Ouster heads into the week after its Q1 earnings release with a notable tension: the founder is consistently selling, a key analyst just downgraded, and shorts are quietly rebuilding their position — all while the stock has staged its best month in recent memory.
The insider activity is the most concrete signal this week. Founder and CTO Mark Frichtl sold roughly 94,600 shares across five separate transactions between April 20 and May 5, realising around $2.9 million in total proceeds at prices between $26 and $30. A director, Stephen Skaggs, added $290,000 in sales across two of those same sessions. The selling accelerated into the post-earnings bounce. Against that, independent director Virginia Boulet made a modest purchase of 1,658 shares on May 11 at around $25, a symbolic buy that barely registers against the scale of the exits. The 90-day net figure tells the fuller story: net insider sales of roughly $9.4 million in value over the period, a meaningful vote against the current price level from the people who know the company best.
Short positioning reinforces the caution. Short interest rose 9% across the week to 9.6% of the free float — a meaningful rebuild after hitting a 30-day low of around 8.5% in late April. Looking further back, shorts were running above 10.8% in early April before covering aggressively through mid-month. The current level sits roughly midway between those two extremes. Availability in the lending pool is around 38%, which means borrow is neither desperately tight nor abundant — there is room for shorts to add if conviction grows. Borrowing costs remain low at 0.46%, having barely moved over the past month, so there is no financial squeeze pressure building on existing short positions.
Options traders are not showing much conviction either way. The put/call ratio of 0.32 is almost exactly in line with its 20-day average, carrying a z-score close to zero. That is striking context: the 52-week range for the PCR spans 0.17 to 1.11, meaning the current reading sits near the bottom of the historical range — call-side activity has broadly dominated for months. What changed this week is that the PCR ticked back up from its mid-April lows as the stock pulled back 5.2% from its recent highs. The signal is consistent with an options market that ran bullishly through the rally but is not yet pricing in serious downside.
The Street picture is mixed. Cantor Fitzgerald downgraded the stock to Neutral immediately after Q1 results on May 7, reversing an upgrade it had only initiated in November 2025. That move matters: Cantor was an active bull on the name and its retreat signals post-earnings disappointment despite the consensus still sitting at Buy, with five buy ratings against one hold. Amerx initiated coverage at Buy on May 11 with a $43 target, partially offsetting the downgrade in headline count. Rosenblatt holds its Buy at $40. The company's own medium-term targets — 30–50% annual revenue growth, gross margins of 35–40% — underpin the bull case, while bears point to persistently negative EPS (earnings yield of -0.67%), a P/B of 6.5x, and a negative EV/EBITDA that has worsened sharply over the past 30 days. One standout: the company ranks in the 94th percentile for EPS surprise, suggesting it has consistently beaten depressed expectations even while losing money.
The stock is up 31% over the past month, closing at $27.10 on May 12, but it lost 5.2% on the week as the post-earnings bounce faded. Closest peer AEVA surged 22.9% on the day and 25.3% on the week — a sharp divergence that suggests some sector-level momentum is present but not flowing uniformly to OUST. INVZ added 14% on the week. The next earnings event is flagged for June 17. Between now and then, the key variables to watch are whether Frichtl's selling pace continues at current prices and whether short interest breaks above the 10% level that marked the early-April peak.
See the live data behind this article on ORTEX.
Open OUST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
